Day Lab News
Spinraza, the first FDA-approved drug that addresses the underlying cause of SMA, is now available commercially in the United States.
The Stanford SMA program has helped investigate Spinraza’s effects, and is developing additional treatments.
Infant at Stanford first to get drug for deadly neurodegenerative disease
Spinal Muscular Atrophy Treatment Breakthrough
April 20, 2018
August 24, 2017
New Stanford drug saves child with deadly genetic disease, The Mercury News
December 11, 2017
December 6, 2016
August 16, 2016
March 6, 2016
FDA rejects new drugs for Duchenne muscular dystrophy, San Francisco Chronicle (SF Chronicle subscription required to read article)
January 7, 2015
Stanford Biobank Seeks Tissue Samples, Quest mda.org
March 19, 2013
Stanford's New DM Center Focuses on Care & Research, Myotonic Dystrophy Foundation
February 13, 2013
Hunt for ALS cure may aid other diseases, San Francisco Chronicle
Neuromuscular Multidisciplinary Clinic responds to Ice Bucket Challenge
California Pacific Medical Center’s Forbes Norris MDA ALS Research Center challenged Stanford’s Neuromuscular Multidisciplinary Clinic to the Ice Bucket Challenge. Yesterday more than 30 people from the Neurosciences Department, the Rehabilitation Department, the construction team for the new Hoover Two building project, the Integrative Medicine team and the business development team joined the Neuromuscular Team to respond to the challenge. Neuromuscular Clinic Director, John W. Day, MD, PhD, said a few words about the need for ALS research funding and challenged several other teams to do the Ice Bucket Challenge. Stanford’s Neuromuscular Multidisciplinary clinic cares for ALS patients and their families and is involved in ALS research. For more information about ALS and the Ice Bucket Challenge visit icebucketchallenge.org.